Asenapine
Medication to treat schizophrenia / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Asenapine?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.[4][8]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Saphris, Sycrest, Secuado |
Other names | ORG-5222 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610015 |
License data | |
Pregnancy category |
|
Routes of administration | Sublingual, transdermal |
Drug class | Atypical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35% (sublingual), <2% (Oral)[5][6][2][7] |
Protein binding | 95%[5][6][2][7] |
Metabolism | hepatic (glucurinodation by UGT1A4 and oxidative metabolism by CYP1A2)[5][6][2][7] |
Elimination half-life | 24 hours[5][6][2][7] |
Excretion | Kidney (50%), Faecal (40%; ~5–16% as unchanged drug in faeces)[5][6][2][7] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
ECHA InfoCard | 100.059.828 |
Chemical and physical data | |
Formula | C17H16ClNO |
Molar mass | 285.77 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
It was chemically derived via altering the chemical structure of the tetracyclic (atypical) antidepressant, mianserin.[9]
It was initially approved in the United States in 2009[10] and approved as a generic medication in 2020.[11]